{"id":"W3011361209","doi":"10.1136/jitc-2020-000530","title":"A first-in-human phase 1 dose escalation study of spartalizumab (PDR001), an anti–PD-1 antibody, in patients with advanced solid tumors","year":2020,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":87,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Center for Advancing Translational Sciences; National Cancer Institute; Novartis Pharmaceuticals Corporation","keywords":"Medicine; Nausea; Adverse effect; Internal medicine; Response Evaluation Criteria in Solid Tumors; Pharmacokinetics; Gastroenterology; Tolerability; Antibody; Lung cancer; Oncology; Population; Monoclonal antibody; Toxicity; Phases of clinical research; Immunology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002773078,0.0002469455,0.0008157981,0.0002776806,0.0000936764,0.00001993348,0.0001811543,0.00007273884,0.0001671215],"category_scores_gemma":[0.00001503086,0.000194875,0.00015455,0.0004893538,0.00008675415,0.0003500672,0.00001043324,0.000246027,1.650615e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001921786,"about_ca_system_score_gemma":0.0001889467,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0004110656,"about_ca_topic_score_gemma":0.000522321,"domain_scores_codex":[0.9978291,0.0000611723,0.001059206,0.0002725607,0.0004787766,0.0002991958],"domain_scores_gemma":[0.998619,0.00002992866,0.0007518607,0.0002410334,0.0002573052,0.0001009238],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.150451,0.008734377,0.6354318,0.0002915938,0.0007297357,0.00002542022,0.009948977,0.002114801,0.1429953,0.000004668339,0.0000483977,0.04922396],"study_design_scores_gemma":[0.1167454,0.03297134,0.8389878,0.0008985554,0.0000784596,0.000005784772,0.001040848,0.0004783582,0.007815571,0.00001664664,0.0006967652,0.000264502],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9965124,0.001180499,0.00007924635,0.0002930291,0.0001600589,0.00171616,0.00003017921,0.00001223385,0.00001624348],"genre_scores_gemma":[0.9989074,0.0004869748,0.0001689773,0.0002003678,0.00008709096,0.00005249611,0.00002595532,0.00005496989,0.00001570569],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.203556,"threshold_uncertainty_score":0.794677,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02102198637447333,"score_gpt":0.3722325480268819,"score_spread":0.3512105616524085,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}